Interpace Biosciences (IDXG) Tops Q1 EPS by 29c

Interpace Biosciences (OTC: IDXG) reported Q1 EPS of $0.10, $0.29 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $12 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Morgan Stanley Upgrades Coal India Ltd (COAL:IN) to Overweight
• Goldman Sachs Upgrades SK Innovation Co Ltd (096770:KS) to Neutral